Medical - Healthcare Information Services
Compare Stocks
5 / 10Stock Comparison
WORX vs CAH vs MCK vs HCAT vs HSIC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Distribution
Medical - Distribution
Medical - Healthcare Information Services
Medical - Distribution
WORX vs CAH vs MCK vs HCAT vs HSIC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Distribution | Medical - Distribution | Medical - Healthcare Information Services | Medical - Distribution |
| Market Cap | $202K | $43.59B | $92.15B | $113M | $8.09B |
| Revenue (TTM) | $3M | $250.55B | $403.43B | $311M | $13.18B |
| Net Income (TTM) | $-4M | $1.56B | $4.76B | $-178M | $398M |
| Gross Margin | 32.0% | 3.7% | 3.6% | 48.7% | 29.1% |
| Operating Margin | -33.3% | 0.9% | 1.5% | -51.7% | 5.8% |
| Forward P/E | — | 17.9x | 19.3x | 14.1x | 13.3x |
| Total Debt | $2K | $9.35B | $7.39B | $20M | $3.69B |
| Cash & Equiv. | $2M | $3.87B | $5.69B | $51M | $156M |
WORX vs CAH vs MCK vs HCAT vs HSIC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| SCWorx Corp. (WORX) | 100 | 0.1 | -99.9% |
| Cardinal Health, In… (CAH) | 100 | 352.7 | +252.7% |
| McKesson Corporation (MCK) | 100 | 513.8 | +413.8% |
| Health Catalyst, In… (HCAT) | 100 | 4.6 | -95.4% |
| Henry Schein, Inc. (HSIC) | 100 | 122.8 | +22.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: WORX vs CAH vs MCK vs HCAT vs HSIC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
WORX is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.77, Low D/E 0.0%, current ratio 2.72x
CAH carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 20 yrs, beta 0.03, yield 1.1%
- Beta 0.03, yield 1.1%, current ratio 0.94x
- Beta 0.03 vs HCAT's 2.05
- 1.1% yield, 20-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend)
MCK is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
- 348.1% 10Y total return vs CAH's 160.8%
- PEG 0.49 vs HSIC's 4.21
- 16.2% revenue growth vs WORX's -3.7%
Among these 5 stocks, HCAT doesn't own a clear edge in any measured category.
HSIC ranks third and is worth considering specifically for value and quality.
- Lower P/E (13.3x vs 14.1x)
- 3.0% margin vs WORX's -154.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.2% revenue growth vs WORX's -3.7% | |
| Value | Lower P/E (13.3x vs 14.1x) | |
| Quality / Margins | 3.0% margin vs WORX's -154.4% | |
| Stability / Safety | Beta 0.03 vs HCAT's 2.05 | |
| Dividends | 1.1% yield, 20-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +22.0% vs WORX's -91.2% | |
| Efficiency (ROA) | 5.7% ROA vs WORX's -61.6%, ROIC 5.4% vs -14.5% |
WORX vs CAH vs MCK vs HCAT vs HSIC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
WORX vs CAH vs MCK vs HCAT vs HSIC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CAH leads in 3 of 6 categories
HSIC leads 2 • MCK leads 1 • WORX leads 0 • HCAT leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
HSIC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK is the larger business by revenue, generating $403.4B annually — 140195.3x WORX's $3M. HSIC is the more profitable business, keeping 3.0% of every revenue dollar as net income compared to WORX's -154.4%. On growth, WORX holds the edge at +13.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $3M | $250.5B | $403.4B | $311M | $13.2B |
| EBITDAEarnings before interest/tax | $972,248 | $3.2B | $6.8B | -$110M | $1.1B |
| Net IncomeAfter-tax profit | -$4M | $1.6B | $4.8B | -$178M | $398M |
| Free Cash FlowCash after capex | -$2M | $4.4B | $6.0B | -$5M | $561M |
| Gross MarginGross profit ÷ Revenue | +32.0% | +3.7% | +3.6% | +48.7% | +29.1% |
| Operating MarginEBIT ÷ Revenue | -33.3% | +0.9% | +1.5% | -51.7% | +5.8% |
| Net MarginNet income ÷ Revenue | -154.4% | +0.6% | +1.2% | -57.2% | +3.0% |
| FCF MarginFCF ÷ Revenue | -54.0% | +1.8% | +1.5% | -1.5% | +4.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +13.8% | +11.0% | +6.0% | -6.2% | +7.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +63.6% | -19.5% | +37.0% | -2.9% | +14.9% |
Valuation Metrics
HSIC leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, HSIC trades at a 26% valuation discount to MCK's 29.2x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs HSIC's 6.84x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $202,035 | $43.6B | $92.1B | $113M | $8.1B |
| Enterprise ValueMkt cap + debt − cash | -$1M | $49.1B | $93.8B | $82M | $11.6B |
| Trailing P/EPrice ÷ TTM EPS | -0.08x | 28.72x | 29.25x | -0.62x | 21.56x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 17.94x | 19.28x | 14.15x | 13.26x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.75x | — | 6.84x |
| EV / EBITDAEnterprise value multiple | — | 16.01x | 18.74x | — | 10.87x |
| Price / SalesMarket cap ÷ Revenue | 0.07x | 0.20x | 0.26x | 0.36x | 0.61x |
| Price / BookPrice ÷ Book value/share | 0.05x | — | — | 0.45x | 1.79x |
| Price / FCFMarket cap ÷ FCF | — | 23.56x | 17.63x | — | 14.12x |
Profitability & Efficiency
MCK leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-73 for WORX. WORX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to HSIC's 0.77x. On the Piotroski fundamental quality scale (0–9), CAH scores 6/9 vs HSIC's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -73.5% | — | +3.0% | -54.7% | +8.2% |
| ROA (TTM)Return on assets | -61.6% | +2.8% | +5.7% | -27.4% | +3.6% |
| ROICReturn on invested capital | -14.5% | +33.8% | +5.4% | -32.9% | +7.1% |
| ROCEReturn on capital employed | -16.4% | +19.2% | +30.5% | -34.0% | +9.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 | 6 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.00x | — | — | 0.08x | 0.77x |
| Net DebtTotal debt minus cash | -$2M | $5.5B | $1.7B | -$31M | $3.5B |
| Cash & Equiv.Liquid assets | $2M | $3.9B | $5.7B | $51M | $156M |
| Total DebtShort + long-term debt | $1,539 | $9.3B | $7.4B | $20M | $3.7B |
| Interest CoverageEBIT ÷ Interest expense | -0.49x | 6.38x | 33.79x | -4.79x | 4.59x |
Total Returns (Dividends Reinvested)
CAH leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $23 for WORX. Over the past 12 months, CAH leads with a +22.0% total return vs WORX's -91.2%. The 3-year compound annual growth rate (CAGR) favors CAH at 31.5% vs WORX's -76.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -75.8% | -9.5% | -8.5% | -30.3% | -8.2% |
| 1-Year ReturnPast 12 months | -91.2% | +22.0% | +4.6% | -59.9% | +5.9% |
| 3-Year ReturnCumulative with dividends | -98.8% | +127.3% | +106.4% | -86.9% | -11.7% |
| 5-Year ReturnCumulative with dividends | -99.8% | +235.7% | +286.9% | -97.0% | -12.5% |
| 10-Year ReturnCumulative with dividends | -100.0% | +160.8% | +348.1% | -95.9% | +5.3% |
| CAGR (3Y)Annualised 3-year return | -76.9% | +31.5% | +27.3% | -49.2% | -4.0% |
Risk & Volatility
CAH leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CAH is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than HCAT's 2.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CAH currently trades 79.3% from its 52-week high vs WORX's 5.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.77x | 0.03x | 0.04x | 2.05x | 0.73x |
| 52-Week HighHighest price in past year | $13.05 | $233.60 | $999.00 | $5.06 | $89.29 |
| 52-Week LowLowest price in past year | $0.20 | $137.75 | $637.00 | $0.96 | $61.95 |
| % of 52W HighCurrent price vs 52-week peak | +5.7% | +79.3% | +75.3% | +31.4% | +79.0% |
| RSI (14)Momentum oscillator 0–100 | 18.6 | 33.2 | 16.2 | 63.9 | 39.1 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 1.7M | 757K | 720K | 1.2M |
Analyst Outlook
CAH leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CAH as "Buy", MCK as "Buy", HCAT as "Buy", HSIC as "Hold". Consensus price targets imply 57.2% upside for HCAT (target: $3) vs 22.6% for HSIC (target: $86). For income investors, CAH offers the higher dividend yield at 1.10% vs MCK's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | — | $249.67 | $1006.50 | $2.50 | $86.43 |
| # AnalystsCovering analysts | — | 33 | 31 | 22 | 32 |
| Dividend YieldAnnual dividend ÷ price | — | +1.1% | +0.4% | — | — |
| Dividend StreakConsecutive years of raises | 2 | 20 | 17 | — | 1 |
| Dividend / ShareAnnual DPS | — | $2.04 | $2.69 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.8% | +3.4% | +4.4% | +10.5% |
CAH leads in 3 of 6 categories (Total Returns, Risk & Volatility). HSIC leads in 2 (Income & Cash Flow, Valuation Metrics).
WORX vs CAH vs MCK vs HCAT vs HSIC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is WORX or CAH or MCK or HCAT or HSIC a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.
2% revenue growth year-over-year, versus -3. 7% for SCWorx Corp. (WORX). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate Cardinal Health, Inc. (CAH) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — WORX or CAH or MCK or HCAT or HSIC?
On trailing P/E, Henry Schein, Inc.
(HSIC) is the cheapest at 21. 6x versus McKesson Corporation at 29. 2x. On forward P/E, Henry Schein, Inc. is actually cheaper at 13. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 49x versus Henry Schein, Inc. 's 4. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — WORX or CAH or MCK or HCAT or HSIC?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to -99. 8% for SCWorx Corp. (WORX). Over 10 years, the gap is even starker: MCK returned +348. 1% versus WORX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — WORX or CAH or MCK or HCAT or HSIC?
By beta (market sensitivity over 5 years), Cardinal Health, Inc.
(CAH) is the lower-risk stock at 0. 03β versus Health Catalyst, Inc. 's 2. 05β — meaning HCAT is approximately 5933% more volatile than CAH relative to the S&P 500. On balance sheet safety, SCWorx Corp. (WORX) carries a lower debt/equity ratio of 0% versus 77% for Henry Schein, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — WORX or CAH or MCK or HCAT or HSIC?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.
2% versus -3. 7% for SCWorx Corp. (WORX). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to -121. 7% for Health Catalyst, Inc.. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — WORX or CAH or MCK or HCAT or HSIC?
Henry Schein, Inc.
(HSIC) is the more profitable company, earning 3. 0% net margin versus -154. 4% for SCWorx Corp. — meaning it keeps 3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HSIC leads at 5. 7% versus -51. 7% for HCAT. At the gross margin level — before operating expenses — HCAT leads at 48. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is WORX or CAH or MCK or HCAT or HSIC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 49x versus Henry Schein, Inc. 's 4. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Henry Schein, Inc. (HSIC) trades at 13. 3x forward P/E versus 19. 3x for McKesson Corporation — 6. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HCAT: 57. 2% to $2. 50.
08Which pays a better dividend — WORX or CAH or MCK or HCAT or HSIC?
In this comparison, CAH (1.
1% yield), MCK (0. 4% yield) pay a dividend. WORX, HCAT, HSIC do not pay a meaningful dividend and should not be held primarily for income.
09Is WORX or CAH or MCK or HCAT or HSIC better for a retirement portfolio?
For long-horizon retirement investors, Cardinal Health, Inc.
(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), 1. 1% yield, +160. 8% 10Y return). Health Catalyst, Inc. (HCAT) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CAH: +160. 8%, HCAT: -95. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between WORX and CAH and MCK and HCAT and HSIC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: WORX is a small-cap quality compounder stock; CAH is a mid-cap quality compounder stock; MCK is a mid-cap high-growth stock; HCAT is a small-cap quality compounder stock; HSIC is a small-cap quality compounder stock. CAH pays a dividend while WORX, MCK, HCAT, HSIC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.